Thank you for subscribing!
Next Investors Archived May 21, 2018
BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.
Next Investors Archived May 17, 2018
Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.
Finfeed Archived May 16, 2018
Rhythm Biosciences (ASX:RHY) has today announced that coverage of its granted European patent (EP2829881) has been confirmed in 13 jurisdictions.
Finfeed Archived May 14, 2018
Rhythm Biosciences (ASX:RHY) has completed the first phase development of two new antibody reagents.
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 10, 2018
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has today announced its most significant clinical milestone to date — the highly encouraging results of its PTX-200 Phase 1b Breast Cancer trial.
Finfeed Archived Mar 29, 2018
ASX small-cap Prescient Therapeutics (PTX) is bringing two novel cancer drugs to the table; PTX-200 to treat breast cancer, ovarian cancer and acute myeloid leukaemia (AML), and PTX-100 to treat a range of solid and blood cancers.
Finfeed Archived Mar 15, 2018
PharmAust (ASX:PAA), a clinical-stage oncology company, has revealed its new collaboration with Dr Doug Fairlie, a leading cancer researcher based at Victoria’s prestigious Olivia Newton-John Cancer Research Institute (ONJCRI).
Next Investors Archived Mar 13, 2018
This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.
Finfeed Archived Mar 06, 2018
BARD1 Life Sciences (ASX:BD1) has announced additional positive results from its BARD1-Ovarian test, indicating that the test returned 89% sensitivity and 82% specificity.
Finfeed Archived Feb 23, 2018
Merck & Co (NYSE:MRK), one of the largest pharmaceutical companies in the world, has bid A$502 million for ASX-listed Viralytics (ASX:VLA) — a deal that would secure the rights to VLA’s lead immunotherapy cancer drug, Cavatak.
Finfeed Archived Feb 02, 2018
Biotech play BARD1 Life Sciences Limited (ASX:BD1) today announced that it has received a Japanese patent for its BARD1 isoforms.
Finfeed Archived Jan 10, 2018
BARD1 Life Sciences Limited (ASX:BD1) has received positive results from its OC-400 Study that showed BARD1-Ovarian achieved high accuracy for detection of ovarian cancer.
Finfeed Archived Oct 03, 2017
While a diagnosis of cancer is still likely to strike fear into the heart of any patient and their loved ones, treatments for the horrible disease are progressing – and for many cancers, survival rates are steadily heading in the right direction.
Finfeed Archived Sep 26, 2017
MitchelLake’s Robin Block spoke with Leslie Chong, the CEO of Imugene, to find out how technology is changing biotech, and how it is transforming the general understanding of cancer treatment.
Next Investors Archived Aug 09, 2017
It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.
Finfeed Archived Aug 07, 2017
BARD1 Life Sciences (ASX: BD1), a company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer, has gained patent approval from IP Australia for its “BARD1 isoforms in lung and colorectal cancer and use thereof”.
Finfeed Archived Jul 31, 2017
Until now, a one off treatment of Opdivo would cost A$5,000, or over A$100,000 per year. Thanks to the Federal Government, it will now be available for just A$38.80 per treatment, or A$6.30 with a concession card.
Finfeed Archived Jun 16, 2017
Shares in cancer immunotherapy drug developer, Imugene (ASX: IMU) rallied more than 7% on Thursday while the S&P/ASX All Ordinaries index plunged 65.5 points or 1.1%.
Join Our Mailing List
